Therapy of Colorectal Carcinoma with Monoclonal Antibodies (MAb17-1A) Alone and in Combination with Granulocyte Monocyte-Colony Stimulating Factor (GM-CSF)

Transcatheter closure of a ruptured ventricular septum following inferior myocardial infarction and cardiogenic shock

“…The HLA‐A2.1/Trop‐2‐specific CTL clones specifically lysed native human cancer cells, but at lower levels compared to the L cell transfectants. These findings were consistent with earlier reports that MCF‐7 cells are resistant to cytotoxic killing 36. 2001) Flow cytometric analysis demonstrated that MCF‐7 cells only express low levels of ICAM‐1.…”

“…The latter has been utilized as a target for antibody immunotherapy,27, 28, 29, 30, 31, 32, 33, 34 and anti‐Trop‐1 antibodies can cause a significant reduction in mortality and relapse rates of resected colon cancer patients 33. Cellular anti‐Trop‐1 responses have been demonstrated in tumor patients35 and anti‐Trop‐1 CTL are induced efficiently by peptide‐pulsed APC 36. Thus, Trop‐1 is immunogenic in cancer patients and anti‐Trop‐1 immunotherapy can contribute significantly to cancer cure.…”

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients

“…A recent pilot trial found that continuous, low-dose GM-CSF had substantial activity (objective response rate 37%) in heavily pretreated patients with either metastatic breast cancer or female genital tract cancer (Kurbacher et al , 2005). Enhancement of ADCC of human peripheral blood mononuclear cells by GM-CSF has been described (Grabstein et al , 1986; Thomassen et al , 1989), and GM-CSF in conjunction with monoclonal antibodies has been used in clinical trials for the treatment of colorectal carcinoma (Mellstedt et al , 1991; Ragnhammar et al , 1992) and neuroblastoma (Yu et al , 1997). Trial results found that GM-CSF augmented ADCC activity of mononuclear cells and granulocytes against both colorectal cancer cells and neuroblastoma; therapeutic efficacy was demonstrated in these trials (Mellstedt et al , 1991; Ragnhammar et al , 1992; Yu et al , 1997).…”

Histamine and Cytokine Therapy: Paper presented at the annual meeting of the Swedish Oncology Society, Stockholm, 1997

“…Indeed, many immunotherapy regimens aim at enhancing the anti-tumor activity of MO. Such regimens include compounds which expand the population of MO and/or granulocytes and the concomitant use of antibodies which armor these cells with specificity against tumor cells (2). Also, MO are antigen-presenting cells and produce cytokines, including IL-1 and IL-10, which are important for the development of adaptive immune reactions against tumor antigens.…”